119 related articles for article (PubMed ID: 3298471)
1. [The effect of bismuth subnitrate on cisplatin toxicity].
Chen JT; Kurokawa Y; Nakayama K; Saito K; Sakamoto K; Fukuda K; Hirai Y; Hamada T; Fujimoto I; Yamauchi K
Nihon Sanka Fujinka Gakkai Zasshi; 1987 May; 39(5):815-22. PubMed ID: 3298471
[TBL] [Abstract][Full Text] [Related]
2. Citrate enhances the protective effect of orally administered bismuth subnitrate against the nephrotoxicity of cis-diamminedichloroplatinum.
Kondo Y; Himeno S; Satoh M; Naganuma A; Nishimura T; Imura N
Cancer Chemother Pharmacol; 2004 Jan; 53(1):33-8. PubMed ID: 14530870
[TBL] [Abstract][Full Text] [Related]
3. [Prevention of renal toxicity of cisplatin by administration of bismuth subnitrate].
Hamada T; Nishiwaki Y; Kodama T; Hayashibe A; Nukariya N; Sasaki H; Morikawa T; Hirosawa T; Matsuyama T
Gan To Kagaku Ryoho; 1989 Nov; 16(11):3587-93. PubMed ID: 2554815
[TBL] [Abstract][Full Text] [Related]
4. [Determination of urinary N-acetyl-beta-D-glucosaminidase (NAG) excretion as a parameter of nephrotoxicity due to cis-platin and the effect of fosfomycin (FOM) on its nephrotoxicity].
Matsuoka R; Inoue T; Miyamura K; Mizutani K; Koike S; Mori H; Kigawa T
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Nov; 38(11):2037-44. PubMed ID: 3794453
[TBL] [Abstract][Full Text] [Related]
5. [Alleviation of cisplatin toxicity by high-dose bismuth subnitrate and pharmacokinetics of bismuth subnitrate and cisplatin].
Morikawa T; Kawamura E; Komiyama T; Imura N
Nihon Gan Chiryo Gakkai Shi; 1990 Jun; 25(6):1138-45. PubMed ID: 2398299
[TBL] [Abstract][Full Text] [Related]
6. [The pharmacokinetics of cisplatin and its influence on renal function according to different infusion methods (report II)--alleviation of renal impairment by bismuth subnitrate combined with ginseng and tang-koui ten].
Takahashi A; Takagi M; Hishida H; Sakamoto Y; Takagi N; Amano H; Ogura Y
Gan To Kagaku Ryoho; 1989 Jul; 16(7):2405-10. PubMed ID: 2665654
[TBL] [Abstract][Full Text] [Related]
7. [A method of cisplatin administration with the aid of high-dose bismuth subnitrate, and their pharmacokinetics].
Morikawa T; Kawamura E
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1094-8. PubMed ID: 2730014
[TBL] [Abstract][Full Text] [Related]
8. Urinary excretion of beta 2-microglobulin and N-acetyl-beta-D-glucosaminidase in advanced neuroblastoma patients receiving cis-diamminedichloroplatinum(II).
Ikeda H; Nagashima K; Okumura H; Takahashi A; Matsuyama S; Nagamachi Y
Eur J Surg Oncol; 1988 Feb; 14(1):17-20. PubMed ID: 3278937
[TBL] [Abstract][Full Text] [Related]
9. [Acute nephrotoxicity by CDDP (on tubular damage)].
Higuchi K; Negoro Y; Suzuki M; Noguchi M; Nakanishi M; Ishihara M; Nakano M
Gan To Kagaku Ryoho; 1991 Jan; 18(1):85-9. PubMed ID: 1987905
[TBL] [Abstract][Full Text] [Related]
10. [Measurement of creatinine clearance and urinary NAG for the evaluation of cis-platinum induced nephrotoxicity].
Kubota A; Yoshida T; Tsukuda M; Furukawa S; Miyata K; Mochimatsu I; Sawaki S
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2599-605. PubMed ID: 2774590
[TBL] [Abstract][Full Text] [Related]
11. [A clinical evaluation of the protective effect of fosfomycin (FOM) against the cis-diamminedichloroplatinum (CDDP)-induced nephrotoxicity].
Saito M; Masaki T; Kato H; Numasaka K
Hinyokika Kiyo; 1988 May; 34(5):782-9. PubMed ID: 3051938
[TBL] [Abstract][Full Text] [Related]
12. [Clinical investigation of cis-platinum nephrotoxicity in 244 cases of primary lung cancer].
Soejima A; Inoue T; Suzuki M; Waku M; Nakabayashi K; Kitamoto K; Nagasawa T
Nihon Jinzo Gakkai Shi; 1992 Jul; 34(7):801-6. PubMed ID: 1479719
[TBL] [Abstract][Full Text] [Related]
13. [Urinary NAG and gamma-GTP activities as indicators of CDDP renal toxicity: effect of fosfomycin on CDDP renal toxicity].
Yoshida K; Takahashi T; Nakame Y; Saitoh H; Horiuchi S; Kaneoya F; Negishi T
Hinyokika Kiyo; 1986 Sep; 32(9):1237-45. PubMed ID: 2880486
[TBL] [Abstract][Full Text] [Related]
14. [Effects of combination chemotherapy with cis-diamminedichloroplatinum (II) (CDDP) on renal function in patients with urogenital malignancies].
Kawamura J; Hida S; Higashi Y; Yamauchi T; Soeda A; Yoshida O
Hinyokika Kiyo; 1985 Feb; 31(2):207-21. PubMed ID: 4040315
[TBL] [Abstract][Full Text] [Related]
15. [Prophylactic effect of fosfomycin on CDDP nephrotoxicity].
Yogi S; Ikeuchi T; Kai Y
Hinyokika Kiyo; 1989 Apr; 35(4):615-21. PubMed ID: 2735267
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of methods for evaluating the nephrotoxicity of cisplatin].
Suzumori K; Yasui Y; Suzumori K; Yagami Y; Seki T
Gan To Kagaku Ryoho; 1988 Aug; 15(8):2251-6. PubMed ID: 3044273
[TBL] [Abstract][Full Text] [Related]
17. [Studies on serum and urinary alpha 1-microglobulin levels as parameter of the renal function--renal function observed after CDDP administration].
Ujiie T; Maruta H; Ito N
Hinyokika Kiyo; 1988 May; 34(5):790-6. PubMed ID: 2459938
[TBL] [Abstract][Full Text] [Related]
18. [Clinical multivariate statistical analysis of nephrotoxicity induced by cisplatin].
Ding DC
Zhonghua Zhong Liu Za Zhi; 1992 Jan; 14(1):64-6. PubMed ID: 1396050
[TBL] [Abstract][Full Text] [Related]
19. [Usefulness of oral rehydration solution for hydration in cancer chemotherapy: toward the application of outpatient chemotherapy with high-dose Cisplatin therapy-].
Sato J; Kudo K; Hino K; Takahashi K
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1471-6. PubMed ID: 21918344
[TBL] [Abstract][Full Text] [Related]
20. [Cyclic high dose CAP therapy by short-stay admission for ovarian malignancies--to increase total dose of CDDP and to improve quality of life of patients].
Ochiai K; Isonishi S; Kimura E; Yokoyama S; Sasaki H; Arihiro T; Terashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1991 Jan; 43(1):19-25. PubMed ID: 1997612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]